Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non Operating Income (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Non Operating Income data on record, last reported at -$218000.0 in Q4 2025.

  • For Q4 2025, Non Operating Income fell 194.37% year-over-year to -$218000.0; the TTM value through Dec 2025 reached $2.4 million, up 95.47%, while the annual FY2025 figure was $2.4 million, 95.47% up from the prior year.
  • Non Operating Income reached -$218000.0 in Q4 2025 per MIRM's latest filing, down from $395000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $2.1 million in Q1 2025 and bottomed at -$3.1 million in Q4 2023.
  • Average Non Operating Income over 5 years is $27150.0, with a median of -$26000.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: plummeted 3358.82% in 2022, then surged 788.54% in 2023.
  • A 5-year view of Non Operating Income shows it stood at -$17000.0 in 2021, then tumbled by 3358.82% to -$588000.0 in 2022, then plummeted by 420.58% to -$3.1 million in 2023, then skyrocketed by 107.55% to $231000.0 in 2024, then crashed by 194.37% to -$218000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$218000.0 in Q4 2025, $395000.0 in Q3 2025, and $86000.0 in Q2 2025.